What Drug Problem?
Pop quiz . . . which market is valued higher, illegal drugs or prescription drugs?
The EMA’s Shambolic Handling of Glybera
If you can’t see the wood for the trees the common sense response is to do a little thinning and let the light shine through.
Big Pharma’s Vanishing Act
It wasn’t exactly love at first sight back in 1976 when Genentech Inc. became of legal age to go forth and incorporate, but the platonic relationship between biotech and pharma has increasingly mellowed over the ensuing 36 years into an…
In Vaccines and Autism Debates, the Truth is That it’s Trust or Consequences
Editor’s note: Since Dr. Breindl first wrote about vaccines and autism in 2008, the paper linking the MMR vaccine to autism has been retracted by the journal that published it, and its author Andrew Wakefield has lost his medical license….
Profit vs. Value: When Activist Shareholders Attack
Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…
Biotech Fundraising Dips in Q112, But No Need to Panic
I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year.
Biotech Falls For April Fools’ Prank – Again!
The contenders for becoming the April Fool in Life Sciences for 2012 came down to three candidates, but two of them have persisted past the April 1 deadline, thereby removing themselves from consideration.
Want Better Data? Align Professional Incentives
This week, researchers are presenting their latest and greatest at the annual meeting of the American Association of Cancer Research. The excitement of all those novel findings, though, received something of an advance puncturing last week by a commentary in…
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire.
2010-12 Biotech IPOs Not Performing THAT Bad. Really.
What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty pharma firm Clovis Oncology Inc. shared some surprising similarities in how…
Join the Conversation